Kymera Therapeutics price to sales ratio KYMR

Market value divided by revenue over the last twelve months, since 2021.

Today, Oct 23, 2026: 87.7×
5-year median: 34.4×
Against its 5-year history: 80th; percentile: 0 is its lowest day, 100 its highest
5-year range: 11.8× to 191×
Peer median: 7.3×

Kymera Therapeutics' price to sales ratio is 87.7× as of Oct 23, 2026.

That is above its 5-year median of 34.4×, higher than on 80% of days in the last 5 years.

Over that time it ranged from 11.8× in Oct 2023 to 191× in Jul 2026.

The median for 10 biotech stocks of a similar size is 7.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	87.7×	83.0×	191×
2025	134×	27.2×	148×
2024	29.7×	23.1×	45.7×
2023	30.2×	11.8×	44.3×
2022	29.8×	12.0×	40.6×
2021	46.4×	38.8×	52.7×

Against its peers

Companies in Biotechnology nearest Kymera Therapeutics' size, closest first, today.

Company	Price to sales ratio
KYMRKymera Therapeutics	87.7×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
ALNYAlnylam Pharmaceuticals	6.2×
ADMAAdma Biologics	4.7×
Peer median	7.3×

Where Kymera Therapeutics ranks

#63of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Kymera Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.